Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 115

Sort by

Sort Order Select

Journal Articles

Frontline experience with second generation covalent Bruton tyrosine kinase inhibitors for mantle cell lymphoma: A single center experience

Luke Maillie, Stefan Barta, Jordan Carter, Michael Cook, Mitchell Hughes, Daniel Landsburg, Sunita Dwivedy Nasta, Marco Ruella, Stephen Schuster, Jakub Svoboda, Colin Thomas, Emily Tomasulo, Elise Chong

Blood (2025) 146 (Supplement 1): 7119.

https://doi.org/10.1182/blood-2025-7119

Published: 2025

Journal Articles

SMARCA4 deletion enhances CAR T cell cytotoxicity and persistence against cancer

Melody Tan, Josephine Giles, Patrizia Porazzi, Leonel Torres, Luca Paruzzo, Alberto Carturan, Wumesh KC, Yunlin Zhang, Raymone Pajarillo, E. John Wherry, Marco Ruella

Blood (2025) 146 (Supplement 1): 4097.

https://doi.org/10.1182/blood-2025-4097

Published: 2025

Journal Articles

Clinical features and outcomes of patients with non-erythrodermic mycosis fungoides with high blood tumor burden

Blood (2025) 146 (Supplement 1): 560.

https://doi.org/10.1182/blood-2025-560

Published: 2025

Journal Articles

CCR5 blockade: A therapeutic approach to uncouple CART-BCMA expansion from CART-mediated immune toxicities.

Blood (2025) 146 (Supplement 1): 5945.

https://doi.org/10.1182/blood-2025-5945

Published: 2025

Journal Articles

Type II interferon-driven crosstalk between effector memory CART and myeloid cells is associated with CART19 resistance in relapsed refractory large B-cell lymphomas

Blood (2025) 146 (Supplement 1): 5337.

https://doi.org/10.1182/blood-2025-5337

Published: 2025

Journal Articles

Precision targeting of immune-mediated thrombotic thrombocytopenic purpura (iTTP) with chimeric auto-antigen receptor (CAAR) T cells

Roman Khadka, Ivan Cohen, Kalpana Parvathaneni, Jean Lemoine, Seul Jung, Audrey Bochi-Layec, Huiwu Zhao, Morgan Hresko, Don Siegel, Marco Ruella, Vijay Bhoj

Blood (2025) 146 (Supplement 1): 2341.

https://doi.org/10.1182/blood-2025-2341

Published: 2025

Journal Articles

IL18-armored CAR T cells in patients with CLL/SLL and Richter's transformation after prior BTK inhibitor and venetoclax failure

Blood (2025) 146 (Supplement 1): 2394.

https://doi.org/10.1182/blood-2025-2394

Published: 2025

Journal Articles

Precision targeting of autoantibody-producing IGHV1-69+ B cells in immune-mediated thrombotic thrombocytopenic purpura (iTTP) using chimeric antigen receptor T cells

Ivan Cohen, Roman Khadka, Jean Lemoine, Audrey Bochi-Layec, Seul Jung, Ki Hyun Kim, Huiwu Zhao, Morgan Hresko, Don Siegel, Paolo Ghia, Kostas Stamatopoulos, Stephen Schuster, Vijay Bhoj, Marco Ruella

Blood (2025) 146 (Supplement 1): 426.

https://doi.org/10.1182/blood-2025-426

Published: 2025

Journal Articles

Precision targeting of the malignant clone in B-cell malignancies using chimeric antigen receptor T cells against the clonotypic IGHV3-23 B cell receptor

Jean Lemoine, Ivan Cohen, Gabrielle Croston, Audrey Bochi-Layec, David Espie, Ranjani Ramasubramanian, Patrizia Porazzi, Federico Stella, Pedram Bayat, Seul Jung, Anastasia Iatrou, Andreas Agathangelidis, Stephen Schuster, Paolo Ghia, Kostas Stamatopoulos, Marco Ruella

Blood (2025) 146 (Supplement 1): 2348.

https://doi.org/10.1182/blood-2025-2348

Published: 2025

Journal Articles

Early administration of CD20 x CD3 bispecific antibodies 4-6 weeks after CAR-T infusion for patients with residual or progressive large B cell lymphomas

Blood (2025) 146 (Supplement 1): 1952.

https://doi.org/10.1182/blood-2025-1952

Published: 2025

Journal Articles

Duration of lymphopenia after CAR-T cell therapy is associated with increased risk of non-melanoma skin cancers and decreased survival

Emeline Chong, Megan Jones, Guido Ghilardi, Luca Paruzzo, Sunita Dwivedy Nasta, Stefan Barta, Jakub Svoboda, Elise Chong, Jordan Carter, Colin Thomas, Michael Cook, Emily Tomasulo, Marco Ruella, Daniel Landsburg, Stephen Schuster

Blood (2025) 146 (Supplement 1): 3728.

https://doi.org/10.1182/blood-2025-3728

Published: 2025

Journal Articles

Naive CD4+ at apheresis and disease control at infusion are associated with improved efficacy in second-line CAR T-cells

Blood (2025) 146 (Supplement 1): 2755.

https://doi.org/10.1182/blood-2025-2755

Published: 2025

Journal Articles

Epigenetic reprogramming via EZH1/2 inhibition enhances T cell-mediated immunotherapies against multiple myeloma

Patrizia Porazzi, Martina Pucillo, Anushka Anant Padmanabhan, Siena Nason, Zhixuan Zheng, Luca Paruzzo, Matthew Ho, Peter Michener, Federico Stella, Antonio Imparato, Sandra Susanibar-Adaniya, Alfred Garfall, Joseph Fraietta, Marco Ruella

Blood (2025) 146 (Supplement 1): 2160.

https://doi.org/10.1182/blood-2025-2160

Published: 2025

Journal Articles

A newly identified role for IL-5 in regulating CART-associated toxicity and efficacy

Blood (2025) 146 (Supplement 1): 808.

https://doi.org/10.1182/blood-2025-808

Published: 2025

Journal Articles

Delayed neurotoxicity, enterocolitis, and BCMA-CART-associated immune-related adverse events (CirAE) are caused by CD4+ CAR T-cells

Blood (2025) 146 (Supplement 1): 804.

https://doi.org/10.1182/blood-2025-804

Published: 2025

Journal Articles

Phase 2 study of cevostamab consolidation following BCMA CAR T cell therapy: preliminary safety, efficacy, and correlative data from the “STEM” (Sequential T Cell-Engagement for Myeloma) trial

Blood (2025) 146 (Supplement 1): 699.

https://doi.org/10.1182/blood-2025-699

Published: 2025

Journal Articles

Precision targeting of pathogenic B cells and autoantibodies in systemic lupus erythematosus using CAR T cells against the IGHV4-34 B cell receptor

Blood (2025) 146 (Supplement 1): 4120.

https://doi.org/10.1182/blood-2025-4120

Published: 2025

Journal Articles

Large B-cell lymphoma following CD19-directed CART-cell therapy failure: Impact of CAR construct on disease features and outcomes of subsequent therapies

Blood (2025) 146 (Supplement 1): 5501.

https://doi.org/10.1182/blood-2025-5501

Published: 2025

Journal Articles

Trends in muscle and fat metrics and their association with outcomes following CAR T-cell therapy in older adults with non Hodgkin lymphoma.

Gabriel Aleixo, Luca Paruzzo, Rakesh Sharma, Walter Witchey, Marco Ruella, Daniel Landsburg, Stefan Barta, Jakub Svoboda, Stephen Schuster, Elise Chong, Pashna Munshi, Sandra Susanibar, Sunita Dwivedy Nasta

Blood (2025) 146 (Supplement 1): 3553.

https://doi.org/10.1182/blood-2025-3553

Published: 2025

Journal Articles

Title first‑in‑human Phase 1 dose‑finding study (VIPER 101) of dual‑population autologous CD5‑deleted anti-CD5 CAR‑T (Senza5 CART5) cells in Relapsed/Refractory T‑cell lymphomas

Stefan Barta, Stephen Schuster, Jakub Svoboda, Jordan Carter, Elise Chong, Daniel Landsburg, Sunita Dwivedy Nasta, Ruchi Patel, Joseph Fraietta, Colin Thomas, Omar Elghawy, Ran Reshef, Aditya Nimmagadda, Lavanya Peddada, Adam Snook, Nicholas Siciliano, Rosemary Mazanet, Marco Ruella

Blood (2025) 146 (Supplement 1): 4174.

https://doi.org/10.1182/blood-2025-4174

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Frontline experience with second generation covalent Bruton tyrosine kinase inhibitors for mantle cell lymphoma: A single center experience

SMARCA4 deletion enhances CAR T cell cytotoxicity and persistence against cancer

Clinical features and outcomes of patients with non-erythrodermic mycosis fungoides with high blood tumor burden

CCR5 blockade: A therapeutic approach to uncouple CART-BCMA expansion from CART-mediated immune toxicities.

Type II interferon-driven crosstalk between effector memory CART and myeloid cells is associated with CART19 resistance in relapsed refractory large B-cell lymphomas

Precision targeting of immune-mediated thrombotic thrombocytopenic purpura (iTTP) with chimeric auto-antigen receptor (CAAR) T cells

IL18-armored CAR T cells in patients with CLL/SLL and Richter's transformation after prior BTK inhibitor and venetoclax failure

Precision targeting of autoantibody-producing IGHV1-69+ B cells in immune-mediated thrombotic thrombocytopenic purpura (iTTP) using chimeric antigen receptor T cells

Precision targeting of the malignant clone in B-cell malignancies using chimeric antigen receptor T cells against the clonotypic IGHV3-23 B cell receptor

Early administration of CD20 x CD3 bispecific antibodies 4-6 weeks after CAR-T infusion for patients with residual or progressive large B cell lymphomas

Duration of lymphopenia after CAR-T cell therapy is associated with increased risk of non-melanoma skin cancers and decreased survival

Naive CD4+ at apheresis and disease control at infusion are associated with improved efficacy in second-line CAR T-cells

Epigenetic reprogramming via EZH1/2 inhibition enhances T cell-mediated immunotherapies against multiple myeloma

A newly identified role for IL-5 in regulating CART-associated toxicity and efficacy

Delayed neurotoxicity, enterocolitis, and BCMA-CART-associated immune-related adverse events (CirAE) are caused by CD4+ CAR T-cells

Phase 2 study of cevostamab consolidation following BCMA CAR T cell therapy: preliminary safety, efficacy, and correlative data from the “STEM” (Sequential T Cell-Engagement for Myeloma) trial

Precision targeting of pathogenic B cells and autoantibodies in systemic lupus erythematosus using CAR T cells against the IGHV4-34 B cell receptor

Large B-cell lymphoma following CD19-directed CART-cell therapy failure: Impact of CAR construct on disease features and outcomes of subsequent therapies

Trends in muscle and fat metrics and their association with outcomes following CAR T-cell therapy in older adults with non Hodgkin lymphoma.

Title first‑in‑human Phase 1 dose‑finding study (VIPER 101) of dual‑population autologous CD5‑deleted anti-CD5 CAR‑T (Senza5 CART5) cells in Relapsed/Refractory T‑cell lymphomas

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only